A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

• Status: Not yet recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 3, Prospective, Randomized, Double-masked, Placebo-controlled, Parallel-design, Multicenter Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated with Cataract Surgery

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: EyePoint Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• Male or female subjects at least 40 years of age scheduled for cataract surgery

• Best corrected visual acuity (BCVA) of 20/30-20/200 in the study eye

• Must be considered by the investigator to have visual (VA) acuity potential greater than 20/30 in the study eye.

Exclusion Criteria:

• Use of any corticosteroids within 7 days prior to Day 0

• Injection of any corticosteroids, systemic immunomodulators or alkylating agents into any body tissue within 90 days

• Score greater than "0" on the Ocular Pain Assessment in the study eye at Screening.